At close: December 20 at 4:00:00 PM EST
Pre-Market: 6:41:15 AM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 2 | 1 | 2 |
| Avg. Estimate | -0.24 | -0.31 | -3.26 | -0.82 |
| Low Estimate | -0.24 | -0.37 | -3.26 | -0.86 |
| High Estimate | -0.24 | -0.24 | -3.26 | -0.78 |
| Year Ago EPS | -46.55 | -5.34 | -138.6 | -3.26 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 2 | 1 | 2 |
| Avg. Estimate | 2.5M | 3M | 9.9M | 12.6M |
| Low Estimate | 2.5M | 3M | 9.9M | 12M |
| High Estimate | 2.5M | 3M | 9.9M | 13.2M |
| Year Ago Sales | 3.73M | 2.63M | 14.73M | 9.9M |
| Sales Growth (year/est) | -32.92% | 14.03% | -32.77% | 27.27% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -10.5 | -5.25 | -1.23 | -0.31 |
| EPS Actual | -46.55 | -5.34 | -0.97 | -0.59 |
| Difference | -36.05 | -0.09 | 0.25 | -0.29 |
| Surprise % | -343.33% | -1.80% | 20.70% | -94.78% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.24 | -0.31 | -3.26 | -0.82 |
| 7 Days Ago | -0.23 | -0.32 | -2.65 | -0.85 |
| 30 Days Ago | -0.23 | -0.32 | -2.65 | -0.85 |
| 60 Days Ago | -0.23 | -0.32 | -2.65 | -0.85 |
| 90 Days Ago | -0.17 | -0.88 | -5.95 | -0.35 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | -- | 1 |
| Up Last 30 Days | 1 | 1 | -- | 1 |
| Down Last 7 Days | -- | -- | 1 | -- |
| Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NBY | 99.48% | 94.29% | 97.65% | 74.85% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Maintains | Ascendiant Capital: Buy to Buy | 11/11/2024 |
| Maintains | Ladenburg Thalmann: Buy to Buy | 8/11/2023 |
Related Tickers
CHRO Channel Therapeutics Corporation
0.6435
-1.45%
ONCO Onconetix, Inc.
0.3469
-3.64%
WINT Windtree Therapeutics, Inc.
0.3202
-1.48%
AZTR Azitra, Inc.
0.4150
+5.01%
SLRX Salarius Pharmaceuticals, Inc.
1.5500
+9.93%
GRI GRI Bio, Inc.
0.7400
-3.90%
QLGN Qualigen Therapeutics, Inc.
3.9000
-1.52%
PTIX Protagenic Therapeutics, Inc.
0.6001
-7.68%
NLSP NLS Pharmaceutics AG
1.9500
-18.07%
CYCC Cyclacel Pharmaceuticals, Inc.
0.3174
-4.11%